Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Eylea's Crossroads | Explore Regeneron's strategy to maintain Eylea's market dominance amidst biosimilar competition and the transition to Eylea HD formulation |
Dupixent's Ascendancy | Discover how Dupixent's expansion into COPD and other indications is driving Regeneron's growth, with analysts projecting significant revenue potential |
Pipeline Potential | Delve into Regeneron's diverse pipeline, including promising oncology and obesity programs, and their potential to shape the company's future |
Financial Outlook | Analyst price targets for Regeneron range from $1015 to $1300, reflecting optimism about the company's growth prospects and pipeline developments |
Metrics to compare | REGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREGNPeersSector | |
---|---|---|---|---|
P/E Ratio | 18.8x | −1.3x | −0.7x | |
PEG Ratio | 1.24 | −0.03 | 0.00 | |
Price/Book | 3.0x | 0.3x | 2.6x | |
Price / LTM Sales | 6.3x | 2.2x | 3.2x | |
Upside (Analyst Target) | 37.1% | 471.7% | 45.2% | |
Fair Value Upside | Unlock | 44.7% | 7.0% | Unlock |